



PAC-03

Version number (1.0)

Effective date (01 Jun 2026)

## REPORTING AND REVIEWING SERIOUS ADVERSE EVENTS

### Definitions

- **Adverse Event (AE):** Any unfavorable or unintended sign, symptom, or disease temporally associated with the use of a study intervention, whether or not related.
- **Serious Adverse Event (SAE):** Any event that results in death, is life-threatening, requires hospitalization or prolongation of hospitalization, results in disability or incapacity, is a congenital anomaly or birth defect.
- **Suspected Unexpected Serious Adverse Reaction (SUSAR):** An unexpected serious adverse reaction judged to be caused by the study intervention.
- **Unanticipated Problem (UP):** Any incident, experience, or outcome that is unexpected, related to the research, and indicates new or increased risk.
- **Unexpected SAE:** An SAE not previously identified in the investigator's brochure, protocol, or consent documents.
- **Causality:** The assessment of whether the AE/SAE is related to the study intervention.
- **Safety Monitoring Plan:** A predefined system for identifying, assessing, and managing safety events during the study.
- **Safety Report:** A structured report submitted to RNEC describing an AE, SAE, or unanticipated problem.

### 1. Purpose

To define the procedures for timely reporting, review and management of SAEs)/ USAE to protect participants' safety and ensure compliance with ethical and regulatory requirements.

### 2. Scope

This SOP applies to:

- All RNEC approved protocols.
- Investigators, sponsors, and study teams conducting research in Rwanda.
- All SAEs occurring at study sites, regardless of causality.

### 3. Responsibilities

- (1) Principal Investigator (PI):
  - Ensures timely detection, assessment, and reporting of SAEs.
  - Ensures that relevant authorities (Rwanda FDA, RBC, sponsors, DSMBs) are notified as required.
- (2) Study Team:
  - Monitors participants and documents safety events.
- (3) Sponsor:
  - Ensures safety oversight, independent monitoring, and reporting to regulatory bodies.
- (4) RNEC Secretariat:
  - Logs SAE reports, ensures timely review, and escalates urgent cases.
- (5) RNEC Chairperson:
  - Assigns reviewers and may call expedited meetings for urgent cases.
- (6) RNEC Members:
  - Review SAE reports and recommend corrective measures.

## 4. Procedures

### Step 1. Detection and Initial Reporting

- PI/study team documents SAE details immediately upon occurrence.
- Initial report to RNEC within **48 hours** (using SAE Reporting Form)

### Step 2. Follow-Up Reporting

PI submits detailed follow-up report within **10 days**, including:

- Description of event.
- Medical management provided.
- Assessment of causality and expectedness.
- Impact on study protocol and participants.

### Step 3. RNEC Review

- Secretariat logs and assigns reviewers.
- Expedited review for life-threatening/ fatal events.
- Recommendations may include protocol amendment, participant re-consent, or study suspension.

### Step 4. Communication

- Secretariat communicates decision to PI within **5 working days** of review.

## 5. Required Documents

- SAE Initial Report Form (submitted within 48 hrs).
- SAE Follow-Up Report (within 5 working days).
- Hospital/medical records.
- Causality assessment report.
- Corrective and Preventive Action (CAPA) plan.
- Study Monitoring Report DSMB.

## 6. Compliance

Failure to report SAEs on time may result in suspension of the protocol. All unexpected SAEs must be reported immediately and followed up with corrective actions.

## 7. Quality Assurance

RNEC shall:

- Periodically audit expedited decisions
- Review SOP every 3-5 years
- Train staff and reviewers

## 8. References and Ethical Framework

- (1) Law N° 015/2022 of 29/06/2022 relating to research on a human being ([View/Download](#)).
- (2) Ministerial Order N° 002/MoH/2023 of 21/03/2023 relating to Rwanda National Research Ethics Committee on a human being ([View/Download](#)).
- (3) Law N° 003/2018 of 09/02/2018 Establishing the Rwanda Food and Drugs Authority, and Determining its Mission, Organization and Functioning ([View/Download](#)).
- (4) Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Participants (2024) ([View/Download](#))
- (5) CIOMS - International Ethical Guidelines for Health-related Research Involving Humans (2016) ([View/Download](#))
- (6) ICH - Guideline for Good Clinical Practice E6 (R3) [View here](#)
- (7) WHO Standards and Operational Guidance for Ethics Review of Health-Related Research with Human Participants (2011) ([View/Download](#))
- (8) RNEC Ethical Guidelines ([View/Download](#))

## 9. Revision History

| Version | Date       | Summary of changes  |
|---------|------------|---|
| 1.0     | 11-05-2026 | First RNEC SOP for Reporting and Reviewing Serious Adverse Events |